Tower Research Capital LLC (TRC) - ORIC PHARMACEUTICALS INC ownership

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of ORIC PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$46,814
+186.9%
7,738
+268.0%
0.00%0.0%
Q2 2023$16,319
+30690.6%
2,103
-76.8%
0.00%
-50.0%
Q4 2022$53
-99.8%
9,077
+30.3%
0.00%
Q3 2022$22,000
-60.0%
6,967
-42.4%
0.00%
-100.0%
Q2 2022$55,000
-41.5%
12,093
-31.0%
0.00%0.0%
Q1 2022$94,000
+683.3%
17,530
+2056.2%
0.00%
Q4 2021$12,000
-77.4%
813
-67.6%
0.00%
-100.0%
Q3 2021$53,000
+65.6%
2,510
+34.7%
0.00%0.0%
Q2 2021$32,000
-15.8%
1,863
+20.0%
0.00%0.0%
Q1 2021$38,000
-57.3%
1,552
-41.1%
0.00%
-66.7%
Q4 2020$89,000
-53.9%
2,635
-65.9%
0.00%
+50.0%
Q3 2020$193,000
+1186.7%
7,728
+1664.4%
0.00%
+100.0%
Q2 2020$15,0004380.00%
Other shareholders
ORIC PHARMACEUTICALS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Column Group LLC 4,768,181$116,820,00011.19%
Memorial Sloan Kettering Cancer Center 602,272$14,756,0009.10%
Euclidean Capital LLC 996,734$24,420,0008.17%
Invus Financial Advisors, LLC 1,007,575$24,686,0005.66%
EcoR1 Capital, LLC 3,092,218$75,759,0003.36%
Ally Bridge Group (NY) LLC 413,061$10,120,0001.94%
EMERALD ADVISERS, LLC 615,511$15,080,0000.54%
Orbimed Advisors 2,337,574$57,271,0000.54%
EMERALD MUTUAL FUND ADVISERS TRUST 624,210$15,293,0000.51%
Casdin Capital, LLC 601,515$14,737,0000.44%
View complete list of ORIC PHARMACEUTICALS INC shareholders